163 related articles for article (PubMed ID: 23764425)
1. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers.
Hagerstrand D; Tong A; Schumacher SE; Ilic N; Shen RR; Cheung HW; Vazquez F; Shrestha Y; Kim SY; Giacomelli AO; Rosenbluh J; Schinzel AC; Spardy NA; Barbie DA; Mermel CH; Weir BA; Garraway LA; Tamayo P; Mesirov JP; Beroukhim R; Hahn WC
Cancer Discov; 2013 Sep; 3(9):1044-57. PubMed ID: 23764425
[TBL] [Abstract][Full Text] [Related]
2. Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer.
Jung V; Kindich R; Kamradt J; Jung M; Müller M; Schulz WA; Engers R; Unteregger G; Stöckle M; Zimmermann R; Wullich B
Mol Cancer Res; 2006 Mar; 4(3):169-76. PubMed ID: 16547154
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.
Nanjundan M; Cheng KW; Zhang F; Lahad J; Kuo WL; Schmandt R; Smith-McCune K; Fishman D; Gray JW; Mills GB
Mol Oncol; 2008 Aug; 2(2):164-81. PubMed ID: 19383336
[TBL] [Abstract][Full Text] [Related]
4. Phospholipid Scramblase 1, an interferon-regulated gene located at 3q23, is regulated by SnoN/SkiL in ovarian cancer cells.
Kodigepalli KM; Anur P; Spellman P; Sims PJ; Nanjundan M
Mol Cancer; 2013 Apr; 12():32. PubMed ID: 23621864
[TBL] [Abstract][Full Text] [Related]
5. The chromosome 3q26 OncCassette: A multigenic driver of human cancer.
Fields AP; Justilien V; Murray NR
Adv Biol Regul; 2016 Jan; 60():47-63. PubMed ID: 26754874
[TBL] [Abstract][Full Text] [Related]
6. Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer.
Linxweiler M; Linxweiler J; Barth M; Benedix J; Jung V; Kim YJ; Bohle RM; Zimmermann R; Greiner M
Am J Pathol; 2012 Feb; 180(2):473-83. PubMed ID: 22197383
[TBL] [Abstract][Full Text] [Related]
7. The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers.
Qian J; Hassanein M; Hoeksema MD; Harris BK; Zou Y; Chen H; Lu P; Eisenberg R; Wang J; Espinosa A; Ji X; Harris FT; Rahman SM; Massion PP
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3469-74. PubMed ID: 25733852
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma.
Liu Y; Yin N; Wang X; Khoor A; Sambandam V; Ghosh AB; Fields ZA; Murray NR; Justilien V; Fields AP
Cell Rep; 2020 Jan; 30(3):771-782.e6. PubMed ID: 31968252
[TBL] [Abstract][Full Text] [Related]
9. SNHG14 promotes the tumorigenesis and metastasis of colorectal cancer through miR-32-5p/SKIL axis.
Ye T; Zhang N; Wu W; Yang B; Wang J; Huang W; Tang D
In Vitro Cell Dev Biol Anim; 2019 Dec; 55(10):812-820. PubMed ID: 31471872
[TBL] [Abstract][Full Text] [Related]
10. SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis.
Ma F; Ding MG; Lei YY; Luo LH; Jiang S; Feng YH; Liu XL
Cell Death Dis; 2020 Dec; 11(12):1028. PubMed ID: 33268765
[TBL] [Abstract][Full Text] [Related]
11. SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma.
Gen Y; Yasui K; Zen Y; Zen K; Dohi O; Endo M; Tsuji K; Wakabayashi N; Itoh Y; Naito Y; Taniwaki M; Nakanuma Y; Okanoue T; Yoshikawa T
Cancer Genet Cytogenet; 2010 Oct; 202(2):82-93. PubMed ID: 20875870
[TBL] [Abstract][Full Text] [Related]
12. SnoN overexpression is predictive of poor survival in patients with esophageal squamous cell carcinoma.
Akagi I; Miyashita M; Makino H; Nomura T; Hagiwara N; Takahashi K; Cho K; Mishima T; Takizawa T; Tajiri T
Ann Surg Oncol; 2008 Oct; 15(10):2965-75. PubMed ID: 18612694
[TBL] [Abstract][Full Text] [Related]
13. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
14. Recurrent copy number gains drive PKCι expression and PKCι-dependent oncogenic signaling in human cancers.
Liu Y; Justilien V; Fields AP; Murray NR
Adv Biol Regul; 2020 Dec; 78():100754. PubMed ID: 32992230
[TBL] [Abstract][Full Text] [Related]
15. 3q26 Amplification and polysomy of chromosome 3 in squamous cell lesions of the lung: a fluorescence in situ hybridization study.
Pelosi G; Del Curto B; Trubia M; Nicholson AG; Manzotti M; Veronesi G; Spaggiari L; Maisonneuve P; Pasini F; Terzi A; Iannucci A; Viale G
Clin Cancer Res; 2007 Apr; 13(7):1995-2004. PubMed ID: 17404079
[TBL] [Abstract][Full Text] [Related]
16. Integrated genomic, transcriptomic, and RNA-interference analysis of genes in somatic copy number gains in pancreatic ductal adenocarcinoma.
Samuel N; Sayad A; Wilson G; Lemire M; Brown KR; Muthuswamy L; Hudson TJ; Moffat J
Pancreas; 2013 Aug; 42(6):1016-26. PubMed ID: 23851435
[TBL] [Abstract][Full Text] [Related]
17. SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells.
Kodigepalli KM; Dutta PS; Bauckman KA; Nanjundan M
FEBS Lett; 2013 Jan; 587(1):5-16. PubMed ID: 23178716
[TBL] [Abstract][Full Text] [Related]
18. SnoN/SKIL modulates proliferation through control of hsa-miR-720 transcription in esophageal cancer cells.
Shinozuka E; Miyashita M; Mizuguchi Y; Akagi I; Kikuchi K; Makino H; Matsutani T; Hagiwara N; Nomura T; Uchida E; Takizawa T
Biochem Biophys Res Commun; 2013 Jan; 430(1):101-6. PubMed ID: 23154181
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ZNF746 suppresses invasion and epithelial to mesenchymal transition in H460 non-small cell lung cancer cells.
Kim B; Sohn EJ; Jung JH; Shin EA; You OH; Im J; Kim SH
Oncol Rep; 2014 Jan; 31(1):73-8. PubMed ID: 24145959
[TBL] [Abstract][Full Text] [Related]
20. Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.
Annala M; Kivinummi K; Tuominen J; Karakurt S; Granberg K; Latonen L; Ylipää A; Sjöblom L; Ruusuvuori P; Saramäki O; Kaukoniemi KM; Yli-Harja O; Vessella RL; Tammela TL; Zhang W; Visakorpi T; Nykter M
Oncotarget; 2015 Mar; 6(8):6235-50. PubMed ID: 25749039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
